Ann: Cynata to Acquire IP from Tekcyte, page-33

First 33 Last

Share
Profile

Follow
JB1975

2,073 Posts.

1185

01/07/24

20:48

Post #: 74556185
Share

Originally posted by JB1975: ↑

this is $230k.230K is enough to pay Kilian's salary for about half a year.

It is a critical component of using iPSC derived MSCs to treat wounds.I don't accept that. Its a discretionary payment now that doesn't seem to be needed to be made now as opposed to later.

Without it, we either develop our own (how much do you think that would cost?), or pay a royalty per bandage (how much do you think that would cost?), or just simply avoid the wound space.

Paying a royalty per bandage is exactly what I would prefer to see happen as if there is no product there is no royalties to pay.

Let the Tekcyte IP holders (and any others that want to use CYP cells to develop any anxiliary technology) show some patience and wear some risk like shareholders that aren't directors have to show some patience and wear some risk. If they have that sort of patience and share that sort of risk fair enough if they get some royalties if their product component is commercial.

It would cost nothing because its out of future profits only if there are any.

Given it's worth 10-11 figures per annum, USD, that would be an outrageous decision, given the positive pre-clinical data.That (10-11 figures) is not a premise I will grant merely because its been placed on an MST slide. Its too easy to produce those miles away figures.

We are not at phase 2 yet even in DFU. This is not the model that has been promoted.

I think the new hire to chase partners has been hired too soon. I think Kilian is incurring expenses he doesn't need to incur this early.

I fear he and the directors with the support of so called sophs will move the company towards an exit at way under $2.

Meaningless announcements of no intrinsic value add can be used to fluff up share prices - but the share prices don't actually represent real value creation when that happens.

Any real positive announcement on results would create real intrinsic value - but you aren't waiting for that. Neither is Kilian.

I will not believe Kilian has entrepreneurial talent (and pay a premium for that - nor do I think the market will) in the absence of any evidence of that.

He has to show entrepreneurial talent (deal-making talent) to get credit for having any. He hasn't done that yet. If in future this turns out to have been a great deal (paying 230k to get clear ownership) - then you can point me back to this time where I've expressed doubts - but until then it you that is expressing your faith not me that is demonstrating any lack of business understanding in my opinion. .

Expand

Also - students can no more pay for a roast chook with $230,000 worth of CYP shares without selling them either. Academic credit is not nothing - its what the Nature Medicine article had.

And the same argument you are making about needing to have all aspects of a technological solution bundled up free and clear applies to having 3D manufacturing solutions not just 2D manufacturing solutions. Kilian said - with cells - the process is the product. Well 3D manufacturing is a different process to 2D manufacturing. Cynata doesn't have currently and doesn't appear to be developing currently a 3D manufactured product. Any partner needing to develop that could only see Cynata as having a partial manufacturing solution and pay accordingly for only part of a manufacturing solution.

CYP Price at posting: 29.5¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

MND

Monadelphous profits up 16.2% on strong revenue result, and the market likes it

USL

'Joaquin Silver District' acquisition to become a key asset for Unico

CC9

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

UNT

UNITH hard launching AI 'digital human' platform too 600+ companies as AI thematic survives sell-off

INA

Ingenia shares jump 7% on strong revenue and earnings figures

There are more pages in this discussion • 41 more messages in this thread...

First 33 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 20.0¢		Change -0.005(2.44%)		Mkt cap ! $36.11M

Open	High	Low	Value	Volume
20.5¢	21.5¢	20.0¢	$6.263K	30.66K

Buyers (Bids)

No.	Vol.	Price($)
6	244227	20.0¢

Sellers (Offers)

Price($)	Vol.	No.
23.0¢	140369	1

View Market Depth

No.	Vol.	Price($)
6	244227	0.200
2	68825	0.195
2	25789	0.190
2	5055	0.180
3	7139	0.175

Price($)	Vol.	No.
0.230	140369	1
0.240	10000	1
0.250	2225	1
0.255	192726	2
0.270	30000	1

Last trade - 15.56pm 20/08/2024 (20 minute delay)

CYP (ASX) Chart

Ann: Cynata to Acquire IP from Tekcyte, page-33

Monadelphous profits up 16.2% on strong revenue result, and the market likes it

'Joaquin Silver District' acquisition to become a key asset for Unico

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

UNITH hard launching AI 'digital human' platform too 600+ companies as AI thematic survives sell-off

Ingenia shares jump 7% on strong revenue and earnings figures

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Cynata to Acquire IP from Tekcyte, page-33

Top Stories

Monadelphous profits up 16.2% on strong revenue result, and the market likes it

'Joaquin Silver District' acquisition to become a key asset for Unico

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

UNITH hard launching AI 'digital human' platform too 600+ companies as AI thematic survives sell-off

Ingenia shares jump 7% on strong revenue and earnings figures

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News